Importantly, the data presented in this work supports the application of chemical Ku–DNA binding inhibition to abrogate DNA-PKcs autophosphorylation, impact DSB repair, modulate DDR signaling, and ultimately impacting cancer cell death, and thus is a promising approach as part of an anticancer therapeutic strategy in combination with DNA DSB-inducing agents. Here, PRKDC is linked to cancer.